9 completed, 3 active not recruiting, 1 terminated. 6 Phase 1, 4 Phase 2, 3 Phase 3.
By phase and status
Follow Alumis Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
envudeucitinib - Hepatic Impairment | Phase 1 | Completed | Alumis Inc | 32 | 2025-04-29 | 2026-05-12 |
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
ESK-001 - Renal Impairment | Phase 1 | Completed | Alumis Inc | 16 | 2025-04-23 | 2025-12-10 |
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo - Plaque Psoriasis, Psoriasis (PsO) | Phase 3 | Active not recruiting | Alumis Inc | 1680 | 2025-01-08 | 2026-04-13 |
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Envudeucitinib, Placebo, Apremilast - Plaque Psoriasis | Phase 3 | Completed | Alumis Inc | 862 | 2024-08-20 | 2026-08-10 |
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Envudeucitinib, Apremilast, Placebo - Plaque Psoriasis | Phase 3 | Completed | Alumis Inc | 912 | 2024-07-25 | 2026-08-10 |
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001
ESK-001, Moxifloxacin (400 mg), Placebo - Healthy Volunteer | Phase 1 | Completed | Alumis Inc | 52 | 2024-06-21 | 2026-01-30 |
An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005
A-005, Placebo - Healthy Volunteer | Phase 1 | Completed | Alumis Inc | 135 | 2024-04-22 | 2026-03-02 |
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
Envudeucitinib, Placebo - SLE | Phase 2 | Active not recruiting | Alumis Inc | 408 | 2023-06-26 | 2026-07-21 |
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
ESK-001 - Uveitis Posterior Non-Infectious, Uveitis, Intermediate | Phase 2 | Terminated | Alumis Inc | 36 | 2023-06-14 | 2024-08-28 |
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
envudeucitinib - Plaque Psoriasis | Phase 2 | Active not recruiting | Alumis Inc | 165 | 2023-01-17 | 2026-07-28 |
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
ESK-001, Placebo - Plaque Psoriasis | Phase 2 | Completed | Alumis Inc | 228 | 2022-09-27 | 2025-06-18 |
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
Experimental drug: ESK-001, Placebo - Safety and Tolerability | Phase 1 | Completed | Alumis Inc | 49 | 2022-05-12 | 2023-05-09 |
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
ESK-001, Rabeprazole - Pharmacokinetics | Phase 1 | Completed | Alumis Inc | 14 | 2022-03-17 | 2023-05-09 |
Conditions studied
Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Lupus Erythematosus, Systemic (1) · Psoriasis (1) · Renal Insufficiency (1) · Uveitis, Intermediate (1)
Interventions
apremilast (2) · Moxifloxacin (1) · Rabeprazole (1)
Countries
United States (13) · Canada (5) · Germany (4) · Poland (4) · Bulgaria (3) · Czechia (3) · Hungary (3) · Puerto Rico (3) · South Korea (3) · Spain (3) · Australia (2) · Estonia (2) · France (2) · Japan (2) · Latvia (2)
Top investigators
Jorn Drappa, Medical Director (3) · Jorn Drappa, MD, Ph.D. (1) · Mark Bradley (1)
Results publications
PMID 40659116, PMID 41061968